{"SPADE_N_13743": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_13743", "Peptide Name": "Brevibacillin 2V (Bre 2V; natural AMPs; nonribosomal peptide, XXL; lipopeptide; XXw1; Val-rich 46%; bacteria, prokaryotes)", "Source": "Brevibacillus laterosporusDSM 25", "Family": "Not found", "Gene": "Not found", "Sequence": "TLKVVVKVVKYLV", "Sequence Length": 13, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anti-MRSA"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 1487.91, "PI": 10.0, "Hydrophobicity": 1.47, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Zhao X, Wang X, Shukla R, Kumar R, Weingarth M, Breukink E, Kuipers OP.2021", "Reference": "Front Microbiol. 2021 Jun 17;12:693725. doi: 10.3389/fmicb.2021.693725.PubMed", "Title": "Brevibacillin 2V, a Novel Antimicrobial Lipopeptide With an Exceptionally Low Hemolytic Activity."}], "Frequent Amino Acids": "VKL", "Absent Amino Acids": "ACDEFGHIMNOPQRSUW", "Basic Residues": 3, "Acidic Residues": 0, "Hydrophobic Residues": 9, "Polar Residues": 11, "Positive Residues": 3, "Negative Residues": 0, "Net Charge": 3, "Comments": "APD analysis reveals this sequence is most similar (92.31%) toBrevibacillin VChemical modification: T1 dehydrated (Dhb); K3=Orithine, N-terminus is acylated with 2-hydroxy-3-methylvaleric acid (lipo); C-terminus is a characteristic valinol (an alcohol form of valine).Activity:  Active against Gram+ S. aureus ATCC15975 (MRSA) (MIC 2 ug/ml), E. faecium LMG16003 (VRE), E. faecalis LMG16216 (VRE), B. cereus ATCC14579 (MIC 2 ug/ml), Gram- A. baumannii ATCC17978 (MIC 32 ug/ml), E. coli ATCC25922 (MIC 16 ug/ml), P. aeruginosa LMG6395 (MIC 64 ug/ml), and K. pneumoniae LMG20218 (MIC 32 ug/ml).Stability: Bevibacillin 2V showed good stability in human plasma.MOA:  Binding to Lipid II (the GlcNAc-MurNAc moiety and/or the pentapeptid) and Permeabilizing Cellular Membranes of S. aureus (MRSA) (Zhao et al. 2021).toxicity:  not hemo.lytic to human RBC at 128 ug/ml. IC50 of HepG2 cells is 45.49 ug/ml. It is less toxic than other natural variants (Bre, Bre V, and Bre I: 5.21-9.89 ug/ml) because of the richness in valines. Updated 7/2021", "Similar Sequences": [{"SPADE_ID": "SPADE_N_13742", "Similarity": 0.9230769230769231, "Sequence": "TLKIVVKVVKYLV"}, {"SPADE_ID": "SPADE_N_07388", "Similarity": 0.9, "Sequence": "LVVVKVVKYL"}, {"SPADE_ID": "SPADE_N_15006", "Similarity": 0.9, "Sequence": "LVVVKVVKYL"}]}}}